AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Sodium channel protein type 11 subunit alpha including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Sodium channel protein type 11 subunit alpha therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Sodium channel protein type 11 subunit alpha, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Sodium channel protein type 11 subunit alpha. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Sodium channel protein type 11 subunit alpha. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Sodium channel protein type 11 subunit alpha includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Sodium channel protein type 11 subunit alpha
partner:
Reaxense
upacc:
Q9UI33
UPID:
SCNBA_HUMAN
Alternative names:
Peripheral nerve sodium channel 5; Sensory neuron sodium channel 2; Sodium channel protein type XI subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.9; hNaN
Alternative UPACC:
Q9UI33; A6NN05; C9JD48; C9JR31; Q68K15; Q8NDX3; Q9UHE0; Q9UHM0
Background:
The Sodium channel protein type 11 subunit alpha, known as Nav1.9, plays a crucial role in the voltage-dependent sodium ion permeability of excitable membranes. It switches between opened or closed conformations based on the voltage difference across the membrane, forming a sodium-selective channel. This tetrodotoxin-resistant sodium channel isoform, with NTRK2's contribution, facilitates rapid BDNF-evoked neuronal depolarization.
Therapeutic significance:
Nav1.9's involvement in hereditary sensory and autonomic neuropathy 7 (HSAN7) and familial episodic pain syndrome 3 highlights its therapeutic potential. Understanding Nav1.9's function could lead to novel treatments for these debilitating conditions, offering hope for patients suffering from congenital pain insensitivity and paroxysmal extremity pain.
